title: [Humoral imunity to pertussis in children with diabetes of type 1].
abstract: To determine the state of humoral immunity to pertussis in children with insulin-dependent diabetes, IgG antibodies to pertussis toxin (PT) were determined in blood serum samples by means of EIA. In a group of children aged up to 6 years the highest percentage (100%) received the complete course of vaccination against pertussis with Russian adsorbed DPT vaccine, containing whole-cell pertussis monovaccine, while in a group over 6 years the complete vaccination course (3 vaccinations and 1 revaccination) had 53.4% of children. Pertussis morbidity was considerably higher in nonvaccinated subjects than in children with 4-fold vaccination (p < 0.001). The coefficient of association (Q) was 0.84. Children of all age groups were found to have low and average titers of antibodies to PT. The regressive analysis showed a decrease in antibodies in persons completely immunized against pertussis by the age of 6 years old. The presence of antibodies in nonimmunized persons showed that cases of pertussis or carrier state took place among the population. High titers of antibodies, indicative of recent cases of pertussis, were registered in all age groups, but high titers of antibodies were registered mostly in the group of children over 13 years old (p < 0.05), which confirmed an increase in pertussis morbidity in adolescents. Thus, vaccination against pertussis effectively protected children with diabetes of type 1, aged up to 6 years. For more prolonged protection the vaccination and revaccination of children aged over 4 years old is necessary.
authors.forename: A A
authors.initials: AA
authors.lastname: Tarasova
authors.forename: M P
authors.initials: MP
authors.lastname: Kostinov
authors.forename: E M
authors.initials: EM
authors.lastname: Zaĭtsev
mesh_terms: D000293:Adolescent; D000907:Antibodies, Bacterial / Q000097:blood*; D001886:Bordetella pertussis / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D003922:Diabetes Mellitus, Type 1 / Q000150:complications*; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage*; D015200:Fluoroimmunoassay; D006801:Humans; D007115:Immunization Schedule; D007074:Immunoglobulin G / Q000097:blood*; D007223:Infant; D007273:Injections, Intramuscular; D037342:Pertussis Toxin / Q000276:immunology*; D012189:Retrospective Studies; D012426:Russia; D014611:Vaccination; D014917:Whooping Cough / Q000097:blood* / Q000150:complications* / Q000517:prevention & control
chemical_list: D000907:Antibodies, Bacterial; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D007074:Immunoglobulin G; D037342:Pertussis Toxin